{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:14:02Z","timestamp":1779390842826,"version":"3.53.1"},"reference-count":33,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Special Research Project of National Health Commission Capacity Building and Continuing Education Center","award":["GWJJZX20251008013"],"award-info":[{"award-number":["GWJJZX20251008013"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe temporal trends in initiation, dose intensity, utilisation and potentially inappropriate prescribing of proton pump inhibitors (PPIs) among recent initiators in an urban Chinese outpatient setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective, annual identification of recent PPI initiators using a 1-year washout definition (repeated cross-sectional approach).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Outpatient prescriptions recorded in the hospital information system of Jinshan Hospital Affiliated to Fudan University, Shanghai, China, 2013\u20132021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults aged \u226518 years who initiated PPI and had no PPI prescription in the preceding year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Primary and secondary outcome measures annual initiation rates (overall and stratified by sex, age group, dose intensity and indication), utilisation metrics (defined daily dose\/1000 inhabitants\/day, defined daily cost, drug utilisation index) and components of potentially inappropriate prescribing (indication-related, prophylaxis-related and incomplete diagnosis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 114\u2009241 recent initiators (mean age 48.47 years; 51.43% female), initiation rates increased from 1.79% (95% CI 1.76% to 1.83%) in 2013 to 2.79% (2.74% to 2.83%) in 2021 (p&lt;0.001), with the steepest rise in adults aged 18\u201334 years. High-dose initiation peaked in 2019 and then declined, while standard-dose initiation increased after 2019. Across 2013\u20132021, potentially inappropriate indication-related prescribing decreased (30.94% in 2013 to 10.36% in 2021), whereas prophylaxis-related prescribing remained common.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PPI initiation increased substantially over the past decade, particularly among younger adults. These patterns raise concerns about potential overuse and suboptimal prescribing. The results underscore the need for targeted prescription review and deprescribing-oriented stewardship, with particular attention to young adults, prophylactic indications and dose optimisation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-105381","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:35:16Z","timestamp":1779388516000},"page":"e105381","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Trends, utilisation and appropriateness of proton pump inhibitor prescriptions among recent initiators: a decade-long analysis of patients with a 1-year washout period (2013\u20132021)"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-4886","authenticated-orcid":false,"given":"Yujuan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifang","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026052111351056000_16.5.e105381.1","unstructured":"The NHS Information Centre, Prescribing and Primary Care Services . Prescriptions dispensed in the community: England, Statistics for 2000 to 2010. 2011."},{"key":"2026052111351056000_16.5.e105381.2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4043"},{"key":"2026052111351056000_16.5.e105381.3","unstructured":"Canadian Institute for Health Information . Prescribed drugs spending in Canada, 2016. Ottawa, ON, Available: https:\/\/secure.cihi.ca\/free_products\/Prescribed%20Drug%20Spending%20i n%20Canada_2016_EN_web.pdf"},{"key":"2026052111351056000_16.5.e105381.4","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X12437358"},{"key":"2026052111351056000_16.5.e105381.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13766"},{"key":"2026052111351056000_16.5.e105381.6","unstructured":"Department of Health . Prescription cost analysis: England 2000. London. 2000."},{"key":"2026052111351056000_16.5.e105381.7","unstructured":"Health and Social Care Information Centre, Prescribing and Primary Care Services . Prescription cost analysis England 2011. London. 2012."},{"key":"2026052111351056000_16.5.e105381.8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/imj.12757","article-title":"Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013","volume":"45","author":"Nishtala","year":"2015","journal-title":"Intern Med J"},{"key":"2026052111351056000_16.5.e105381.9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/pds.1969","article-title":"Marked increase in proton pump inhibitors use in Australia","volume":"19","author":"Hollingworth","year":"2010","journal-title":"Pharmacoepidemiol Drug"},{"key":"2026052111351056000_16.5.e105381.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-018-3358-5","article-title":"Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists\u2019 effect on prescribing practice at a tertiary hospital","volume":"18","author":"Luo","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2026052111351056000_16.5.e105381.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-014-0638-6","article-title":"Prescribing efficiency of proton pump inhibitors in China: influence and future directions","volume":"15","author":"Zeng","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"2026052111351056000_16.5.e105381.12","first-page":"2195","article-title":"Expert consensus on optimal application of proton pump inhibitors","volume":"40","author":"Zhang","year":"2020","journal-title":"Chin J Hosp Pharm"},{"key":"2026052111351056000_16.5.e105381.13","first-page":"1","article-title":"Guiding principles for Clinical Application of proton pump inhibitors","volume":"28","year":"2021","journal-title":"China J Pract Rural Phys"},{"key":"2026052111351056000_16.5.e105381.14","first-page":"10","article-title":"Expert consensus on rapid health evaluation of oral proton pump inhibitors in Guangdong Province","volume":"33","author":"Chen","year":"2023","journal-title":"Pharmacy Today"},{"key":"2026052111351056000_16.5.e105381.15","first-page":"673","article-title":"Guiding Principles for the Clinical Application of Proton Pump Inhibitors in Hunan Province (Trial)","volume":"14","author":"Yuan","year":"2016","journal-title":"Central South Pharmacy"},{"key":"2026052111351056000_16.5.e105381.16","first-page":"2769","article-title":"Expert consensus on reasonable application of proton pump inhibitors in zhejiang province Chin","volume":"38","author":"Shi","year":"2021","journal-title":"J Mod Appl Pharm"},{"key":"2026052111351056000_16.5.e105381.17","first-page":"897","article-title":"Pharmaceutical Affairs Management Professional Committee of Chongqing Hospital Association Expert consensus on prescription review rules of proton pump inhibitors","volume":"33","year":"2022","journal-title":"China Pharmacy"},{"key":"2026052111351056000_16.5.e105381.18","unstructured":"WHO . Defined Daily Dose (DDD), 2020. Available: https:\/\/www.who.int\/ toolkits\/atc-ddd-toolkit\/about-ddd"},{"key":"2026052111351056000_16.5.e105381.19","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/pds.5352","article-title":"Proton pump inhibitors long term use-trends and patterns over 15\u2009years of a large health maintenance organization","volume":"30","author":"Rosenberg","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026052111351056000_16.5.e105381.20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00228-019-02798-8","article-title":"Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison","volume":"76","author":"Yu","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026052111351056000_16.5.e105381.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13766"},{"key":"2026052111351056000_16.5.e105381.22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.therap.2018.03.001","article-title":"Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database","volume":"73","author":"Boucherie","year":"2018","journal-title":"Therapie"},{"key":"2026052111351056000_16.5.e105381.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton Pump Inhibitor Use in the U.S. Ambulatory Setting, 2002\u20132009","volume":"8","author":"Rotman","year":"2013","journal-title":"PLoS ONE"},{"key":"2026052111351056000_16.5.e105381.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01106.x"},{"key":"2026052111351056000_16.5.e105381.25","unstructured":"Pharmacy Benefits Management Strategic Health Group . Contract adherence reports national reports: Q4FY99. Washington, DC: Department of Veterans Affairs, Veterans Health Administration, 2000."},{"key":"2026052111351056000_16.5.e105381.26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies","volume":"37","author":"Cheungpasitporn","year":"2015","journal-title":"Ren Fail"},{"key":"2026052111351056000_16.5.e105381.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bonr.2019.100204","article-title":"Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study","volume":"10","author":"Brozek","year":"2019","journal-title":"Bone Rep"},{"key":"2026052111351056000_16.5.e105381.28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamainternmed.2013.2851","article-title":"Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals","volume":"173","author":"Maggio","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2026052111351056000_16.5.e105381.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.16.1955"},{"key":"2026052111351056000_16.5.e105381.30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.17235\/reed.2019.6155\/2019","article-title":"The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China","volume":"111","author":"Ying","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"2026052111351056000_16.5.e105381.31","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.dld.2020.05.005","article-title":"Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation","volume":"52","author":"Giannini","year":"2020","journal-title":"Dig Liver Dis"},{"key":"2026052111351056000_16.5.e105381.32","first-page":"122","article-title":"Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization","volume":"16","author":"Thomas","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"2026052111351056000_16.5.e105381.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.01.021"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-105381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:35:23Z","timestamp":1779388523000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-105381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-105381"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-105381","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}